Advertisement
INCY vs PTCT
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. PTC Therapeutics, Inc. (PTCT) Stock Comparison
Key Takeaways
- INCY boasts a larger market capitalization of approximately $18.8 billion compared to PTCT's $5.7 billion, reflecting greater scale in the biopharmaceutical sector.
- Recent market activity shows INCY gaining about 4.8% over the past month amid upcoming earnings and clinical data presentations.
- PTCT has delivered stronger year-to-date returns around 10%, driven by product launches in rare disorders.
- Analyst price targets suggest upside for both, with INCY at $107 average versus current levels near $95, and PTCT at $88 from around $68.
- Both companies operate in biotech but differ in focus: INCY on oncology and immunology, PTCT on rare genetic diseases.
- Trading volumes indicate solid liquidity, with INCY at over 1 million shares daily versus PTCT's 640,000.
Introduction
Incyte Corporation (INCY) and PTC Therapeutics, Inc. (PTCT) represent key players in the biopharmaceutical industry, focusing on innovative therapies for oncology, immunology, and rare genetic disorders. This stock comparison analyzes their recent performance, business models, and market positioning to assist traders and investors navigating the volatile biotech sector. Those seeking exposure to growth-oriented biotech stocks with distinct pipelines and risk profiles may find value in evaluating relative momentum, analyst sentiment, and upcoming catalysts in the current market environment.
INCY Overview and Recent Performance
Incyte Corporation (INCY) is a biopharmaceutical firm specializing in the discovery, development, and commercialization of oncology and immunology therapeutics, including JAKAFI (ruxolitinib) for myelofibrosis and polycythemia vera, and OPZELURA (ruxolitinib cream) for inflammatory conditions. In recent market activity, INCY shares have traded around $95, within a 52-week range of $58 to $112, supported by a market cap exceeding $18 billion. Sentiment has been bolstered by recent Phase 3 data presentations at the American Society of Clinical Oncology (ASCO) meeting, partnerships such as with Adagene for colorectal cancer therapies, and analyst upgrades, including RBC Capital lifting its target to $95. Upcoming Q1 earnings expectations of revenue growth have contributed to a roughly 5% monthly gain, though shares dipped slightly amid broader sector pressures.
PTCT Overview and Recent Performance
PTC Therapeutics, Inc. (PTCT) develops medicines for rare disorders, with key products like Translarna and Emflaza for Duchenne muscular dystrophy (DMD), Upstaza for AADC deficiency, and the recently launched Safiance for foundational growth. Shares have hovered near $68, with a 52-week range from $36 to $88 and a market cap of about $5.7 billion. Recent performance reflects year-to-date gains around 10%, fueled by global approvals and strong initial uptake of Safiance following Q4 results. Analyst adjustments, including Jefferies' hold rating with a $76 target, have tempered enthusiasm, while price target raises to $77 signal potential in the rare disease pipeline. Trading reflects moderate volume amid pipeline advancements in Huntington's disease and phenylketonuria (PKU).
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots selected from over 350 available models that trade thousands of tickers across stocks, ETFs, and crypto. These curated bots demonstrate impressive stats, including annualized returns ranging from +15% to +168%, win rates up to 88%, and profit factors between 1.5 and 11.7, with average trade durations from hours to weeks. Strategies vary from short-term trend-following in semiconductors and gold miners to volatility plays and multi-agent systems with customizable risk management like TP/SL corridors (e.g., 3% take profit/2% stop loss). Ideal for current market conditions, they cater to diverse styles and timeframes. Explore these high-performing options to enhance your trading edge.
Head-to-Head Comparison
INCY and PTCT both target niche biopharma markets but diverge in focus: INCY's established portfolio emphasizes oncology (e.g., biliary tract cancer, Merkel cell carcinoma) with commercial revenues from JAKAFI, while PTCT prioritizes rare genetic conditions like DMD and SMA via splicing and gene therapies. Growth drivers for INCY include partnerships (e.g., Novartis, Lilly) and clinical readouts, contrasting PTCT's reliance on label expansions and new launches like Safiance. Recent momentum favors PTCT on YTD basis, but INCY shows steadier monthly gains. Risk factors are similar—clinical trial outcomes and regulatory hurdles—but INCY's larger scale offers lower volatility (PE 14.8 vs. 8.0). Market sentiment leans positive for both via analyst targets, with INCY benefiting from broader sector exposure.
Tickeron AI Verdict
Tickeron's AI models would likely favor INCY in the current environment due to its trend consistency, higher analyst target upside relative to size, upcoming earnings catalysts, and lower relative volatility amid recent partnerships and data readouts. While PTCT shows stronger YTD momentum from product momentum, INCY's established positioning and pipeline diversity provide a more probabilistic edge for near-term relative outperformance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Buy and PTCT is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 2 FA rating(s) are green whilePTCT’s FA Score has 0 green FA rating(s).
- INCY’s FA Score: 2 green, 3 red.
- PTCT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 5 TA indicator(s) are bullish while PTCT’s TA Score has 5 bullish TA indicator(s).
- INCY’s TA Score: 5 bullish, 4 bearish.
- PTCT’s TA Score: 5 bullish, 4 bearish.
Price Growth
INCY (@Biotechnology) experienced а +6.01% price change this week, while PTCT (@Biotechnology) price change was +5.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.
Reported Earning Dates
INCY is expected to report earnings on Aug 04, 2026.
PTCT is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (+0.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| INCY | PTCT | INCY / PTCT | |
| Capitalization | 21.7B | 6.23B | 348% |
| EBITDA | 1.87B | -21.5M | -8,704% |
| Gain YTD | 9.882 | -1.080 | -915% |
| P/E Ratio | 15.33 | 7.51 | 204% |
| Revenue | 5.36B | 827M | 648% |
| Total Cash | 4.02B | 1.89B | 212% |
| Total Debt | 39.4M | 395M | 10% |
INCY | PTCT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 60 | 51 | |
SMR RATING 1..100 | 33 | 100 | |
PRICE GROWTH RATING 1..100 | 16 | 46 | |
P/E GROWTH RATING 1..100 | 100 | 43 | |
SEASONALITY SCORE 1..100 | 50 | 38 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (72) in the Biotechnology industry is in the same range as PTCT (99). This means that INCY’s stock grew similarly to PTCT’s over the last 12 months.
PTCT's Profit vs Risk Rating (51) in the Biotechnology industry is in the same range as INCY (60). This means that PTCT’s stock grew similarly to INCY’s over the last 12 months.
INCY's SMR Rating (33) in the Biotechnology industry is significantly better than the same rating for PTCT (100). This means that INCY’s stock grew significantly faster than PTCT’s over the last 12 months.
INCY's Price Growth Rating (16) in the Biotechnology industry is in the same range as PTCT (46). This means that INCY’s stock grew similarly to PTCT’s over the last 12 months.
PTCT's P/E Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for INCY (100). This means that PTCT’s stock grew somewhat faster than INCY’s over the last 12 months.
| INCY | PTCT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 49% | 3 days ago 83% |
| Stochastic ODDS (%) | 3 days ago 57% | 3 days ago 74% |
| Momentum ODDS (%) | 3 days ago 64% | 3 days ago 70% |
| MACD ODDS (%) | 3 days ago 69% | 3 days ago 80% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 78% |
| TrendMonth ODDS (%) | 3 days ago 62% | 3 days ago 77% |
| Advances ODDS (%) | 3 days ago 63% | 3 days ago 78% |
| Declines ODDS (%) | 13 days ago 59% | 13 days ago 79% |
| BollingerBands ODDS (%) | 3 days ago 62% | 5 days ago 86% |
| Aroon ODDS (%) | 5 days ago 56% | N/A |
Advertisement